Carola Riva

6PUBLICATIONS
45CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Respiratory diseasesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Raffaele Palmieri, Fabio Guolo, Luana Fianchi

|Feb 11, 2026
Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Salvatore Perrone, Andrea Corbingi, Calogero Vetro

|Dec 05, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Raffaele Palmieri, Fabio Guolo, Luana Fianchi

|Sep 24, 2025
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Fabio Guolo, Luana Fianchi, Maria Paola Martelli

|Jan 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.

Giovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone

|Dec 05, 2024
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease.

Carola Riva, Paola Minetto, Maria Chies

Pageof 1

Frequent Collaborators

5 joint publications

Calogero Vetro

5 joint publications

Fabio Guolo

4 joint publications

Maria Paola Martelli

4 joint publications

Salvatore Perrone